VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare?) in Comparison to Oxybutynin for Overactive Bladder Patients.
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2010
At a glance
- Drugs Oxybutynin; Solifenacin
- Indications Overactive bladder
- Focus Adverse reactions; Registrational
- Acronyms VECTOR
- Sponsors Astellas Pharma
- 17 Mar 2010 Results published in the Journal of Urology.
- 30 Apr 2009 Results were presented at the American Urological Association Annual Meeting, according to a Astellas Pharma Canada media release.
- 14 Jul 2008 Actual patient number is now 132 as reported by ClinicalTrials.gov.